These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30708267)

  • 1. The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.
    Rossi L; McCartney A; De Santo I; Risi E; Moretti E; Malorni L; Biganzoli L; Di Leo A
    Cancer Treat Rev; 2019 Mar; 74():29-34. PubMed ID: 30708267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
    Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
    Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
    Jinih M; Relihan N; Corrigan MA; O'Reilly S; Redmond HP
    Breast J; 2017 Nov; 23(6):694-705. PubMed ID: 28252242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
    Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
    Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
    Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
    Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
    Pan K; Chlebowski RT
    Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
    Blok EJ; Derks MG; van der Hoeven JJ; van de Velde CJ; Kroep JR
    Cancer Treat Rev; 2015 Mar; 41(3):271-6. PubMed ID: 25698635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renaissance of endocrine therapy in breast cancer.
    Williams N; Harris LN
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):41-7. PubMed ID: 24346127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
    Smith IE; Yeo B; Schiavon G
    Am Soc Clin Oncol Educ Book; 2014; ():e16-24. PubMed ID: 24857098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
    Higgins MJ; Liedke PE; Goss PE
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):23-32. PubMed ID: 23116626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current adjuvant endocrine treatment of breast cancer].
    Dedes KJ; Gabriel N; Fink D
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of adjuvant endocrine therapy for postoperative breast cancer patients].
    Doihara H; Ogasawara Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():563-7. PubMed ID: 17682212
    [No Abstract]   [Full Text] [Related]  

  • 19. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.